文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

一线化疗联合西妥昔单抗或贝伐珠单抗对KRAS野生型晚期或转移性结直肠癌患者总生存期的影响:一项随机临床试验

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

该随机临床试验纳入1137例既往未治疗的KRAS野生型晚期或转移性结直肠癌患者,随机接受西妥昔单抗或贝伐珠单抗联合mFOLFOX6或FOLFIRI化疗。结果显示,西妥昔单抗组与贝伐珠单抗组的中位总生存期分别为30.0个月和29.0个月,差异无统计学意义(分层HR 0.88,95%CI 0.77-1.01,P=0.08)。

要点

  • 在KRAS野生型晚期或转移性结直肠癌一线治疗中,西妥昔单抗联合化疗与贝伐珠单抗联合化疗的总生存期无显著差异。
  • 西妥昔单抗组中位总生存期为30.0个月,贝伐珠单抗组为29.0个月(分层HR 0.88,95%CI 0.77-1.01,P=0.08)。
  • 两组中位无进展生存期分别为10.5个月和10.6个月(分层HR 0.95,95%CI 0.84-1.08,P=0.45)。

核心结论

  • 在既往未治疗的KRAS野生型晚期或转移性结直肠癌患者中,化疗联合西妥昔单抗与化疗联合贝伐珠单抗作为初始生物治疗相比,总生存期无显著差异。

研究设计与样本

  • 随机临床试验,在美国和加拿大国家临床试验网络内的社区和学术中心入组患者(2005年11月至2012年3月),随机接受西妥昔单抗(n=578)或贝伐珠单抗(n=559)联合由治疗医生和患者选择的mFOLFOX6或FOLFIRI化疗。

主要发现

  • 共1137例患者(中位年龄59岁;440例[39%]女性),其中1074例(94%)符合入组标准;截至2015年12月15日,263例存活患者的中位随访时间为47.4个月(范围0-110.7个月),82%的患者(938/1137)出现疾病进展。
  • 西妥昔单抗联合化疗组的中位总生存期为30.0个月,贝伐珠单抗联合化疗组为29.0个月,分层风险比(HR)为0.88(95%CI 0.77-1.01;P=0.08)。
  • 西妥昔单抗联合化疗组的中位无进展生存期为10.5个月,贝伐珠单抗联合化疗组为10.6个月,分层HR为0.95(95%CI 0.84-1.08;P=0.45)。
  • 缓解率分别为西妥昔单抗组59.6%和贝伐珠单抗组55.2%,差异无统计学意义(差异4.4%,95%CI 1.0%-9.0%,P=0.13)。

关键数值与推荐

  • 主要终点为总生存期;次要终点包括无进展生存期和总缓解率(研究者报告的确认或未确认的完全或部分缓解)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown. OBJECTIVE: To determine if the addition of cetuximab vs bevacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superior as first-line therapy in advanced or metastatic KRAS wild-type (wt) colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS: Patients (≥18 years) enrolled at community and academic centers throughout the National Clinical Trials Network in the United States and Canada (November 2005-March 2012) with previously untreated advanced or metastatic colorectal cancer whose tumors were KRAS wt chose to take either the mFOLFOX6 regimen or the FOLFIRI regimen as chemotherapy and were randomized to receive either cetuximab (n = 578) or bevacizumab (n = 559). The last date of follow-up was December 15, 2015. INTERVENTIONS: Cetuximab vs bevacizumab combined with either mFOLFOX6 or FOLFIRI chemotherapy regimen chosen by the treating physician and patient. MAIN OUTCOMES AND MEASURES: The primary end point was overall survival. Secondary objectives included progression-free survival and overall response rate, site-reported confirmed or unconfirmed complete or partial response. RESULTS: Among 1137 patients (median age, 59 years; 440 [39%] women), 1074 (94%) of patients met eligibility criteria. As of December 15, 2015, median follow-up for 263 surviving patients was 47.4 months (range, 0-110.7 months), and 82% of patients (938 of 1137) experienced disease progression. The median overall survival was 30.0 months in the cetuximab-chemotherapy group and 29.0 months in the bevacizumab-chemotherapy group with a stratified hazard ratio (HR) of 0.88 (95% CI, 0.77-1.01; P = .08). The median progression-free survival was 10.5 months in the cetuximab-chemotherapy group and 10.6 months in the bevacizumab-chemotherapy group with a stratified HR of 0.95 (95% CI, 0.84-1.08; P = .45). Response rates were not significantly different, 59.6% vs 55.2% for cetuximab and bevacizumab, respectively (difference, 4.4%, 95% CI, 1.0%-9.0%, P = .13). CONCLUSIONS AND RELEVANCE: Among patients with KRAS wt untreated advanced or metastatic colorectal cancer, there was no significant difference in overall survival between the addition of cetuximab vs bevacizumab to chemotherapy as initial biologic treatment. TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT00265850.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017. PMID: 28632865. doi:10.1001/jama.2017.7105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。